Search

The article presents a study on the development of severe systemic reactions after rituximab infusion in patients with hepatitis C virus-induced mixed cryoglobulinemia (HCV-MC) vasculitis. It is stated in the study that Rituximab, which targets B cell CD20 molecules, is effective in HCV-MC vasculitis. It notes that the study immunochemically analyzed the systemic reactions following rituximab infusion. It also mentions that the study found a formation of a complex leading to severe reactions.

Two letters to the editor are presented in response to the article "Rituximab May Form a complex With IgGK Mixed Cryoglobulin and Induce Severe Systemic Reactions in Patients With Hepatitis C Virus-Induced Vasculitis," by D. Sene and colleagues, published in the 2009 issue of "Arthritis and Rheumatology," including a discussion on the hypothesis presented in the article, and the authors' reply.